Skip to main content

Advertisement

SpringerLink
Log in

Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research

  • Review
  • Published:
Journal of Cancer Survivorship Aims and scope Submit manuscript

Abstract

Purpose

For patients with hormone receptor positive breast cancer, survivorship entails prolonged self-management of adjuvant treatment in the form of daily hormone therapy. Although sustained daily adherence across the 5-year course of therapy is associated with improved recurrence-free survival outcomes, adherence is suboptimal and many women discontinue hormone therapy prematurely. Factors associated with breast cancer survivors’ nonadherence and nonpersistence are not comprehensively understood. Furthermore, psychosocial variables have only received limited research attention, despite their documented relationships with adherence in other chronic illness populations.

Methods

A systematic literature review identified 14 studies that analyzed relationships between psychosocial factors and breast cancer survivors’ adherence and/or persistence with adjuvant hormone therapy.

Results

Although identified relationships were complex and at times inconsistent, salient conclusions emerged. Interpersonal factors, in the form of positive social support and patient-centered interactions with medical providers, as well as intrapersonal factors, such as anxiety and beliefs about the relative benefits of medication use, were reliably associated with better adherence and persistence. Depression did not demonstrate the negative impact on adherence that has been observed in other medical populations. No relationships between quality of life and adherence were identified.

Conclusions

Adjuvant hormone therapy appears to be a unique context for medication adherence, which warrants further attention and more rigorous analysis in future research.

Implications for Cancer Survivors

Individual patients’ psychosocial characteristics and health care preferences should be considered when striving to optimize medication adherence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. American Cancer Society. Breast cancer facts & figures, 2011-2012. Atlanta: American Cancer Society; 2011.

    Google Scholar 

  2. American Cancer Society. Cancer treatment and survivorship facts & figures 2012-2013. Atlanta: American Cancer Society; 2012.

    Google Scholar 

  3. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003;21:28–34.

    Article  CAS  PubMed  Google Scholar 

  4. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92.

    Article  CAS  PubMed  Google Scholar 

  5. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics. CA-Cancer J Clin. 2013. doi:10.3322/caac.21203.

    Google Scholar 

  6. Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in transition. Washington: The National Academies Press; 2005.

    Google Scholar 

  7. Haque R, Ahmed SA, Fisher A, Avila CC, Shi J, Guo A, et al. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med. 2012;1:318–27.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.

    Article  Google Scholar 

  9. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J Clin Oncol. 2010;28:3784–96.

    Article  PubMed  Google Scholar 

  11. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Tr. 2006;100:273–84.

    Article  Google Scholar 

  12. Cella D, Fallowfield L. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Tr. 2008;107:167–80.

    Article  CAS  Google Scholar 

  13. Huiart L, Bouhnik A, Rey D, Tarpin C, Cluze C, Bendiane MK, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer. 2012;48:1939–46.

    Article  PubMed  Google Scholar 

  14. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. British J Cancer. 2013;108:1515–24.

    Article  CAS  Google Scholar 

  15. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. British J Cancer. 2008;99:1763–8.

    Article  CAS  Google Scholar 

  16. Xu S, Yang Y, Tao W, Song Y, Chen Y, Ren Y, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Tr. 2012;136:495–502.

    Article  CAS  Google Scholar 

  17. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189–97.

    CAS  PubMed  Google Scholar 

  18. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Tr. 2012;134:459–78.

    Article  CAS  Google Scholar 

  19. Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Tr. 2013;138:325–8.

    Article  Google Scholar 

  20. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the 5-year course. Breast Cancer Res Treat. 2006;99:215–20.

    Article  PubMed  Google Scholar 

  21. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen. Cancer. 2007;109:832–9.

    Article  CAS  PubMed  Google Scholar 

  22. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–6.

    Article  CAS  PubMed  Google Scholar 

  23. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001;19:322–8.

    CAS  PubMed  Google Scholar 

  24. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;22:3309–15.

    Article  PubMed  Google Scholar 

  25. Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol. 2012;23:882–90.

    Article  CAS  PubMed  Google Scholar 

  26. Liu Y, Malin JL, Diamant AL, Thind A, Maly RC. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Tr. 2012;137:829–36.

    Article  CAS  Google Scholar 

  27. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–7.

    Article  CAS  PubMed  Google Scholar 

  28. DiMatteo RM. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23:207–18.

    Article  PubMed  Google Scholar 

  29. Gallant MP. The influence of social support on chronic illness self-management: a review and directions for research. Health Educ Behav. 2003;30:170–95.

    Article  PubMed  Google Scholar 

  30. Christensen AJ. Patient adherence to medical treatment regimens: bridging the gap between behavioral science and biomedicine. New Haven: Yale University Press; 2004.

    Google Scholar 

  31. Christensen AJ, Howren MB, Hillis SL, Kaboli P, Carter BL, Cvengros JA, et al. Patient and physician beliefs about control over health: symmetrical beliefs predict medication regimen adherence. J Gen Intern Med. 2010;25:397–402.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Cvengros JA, Christensen AJ, Cunningham C, Hillis SL, Kaboli PJ. Patient preference for and reports of provider behavior: impact of symmetry on patient outcomes. Health Psychol. 2009;28:660–7.

    Article  PubMed  Google Scholar 

  33. Fann JR, Thomas-Rich A, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiat. 2008;30:112–26.

    Article  Google Scholar 

  34. Henselmans I, Helgeson VS, Seltman H, de Vries J, Sanderman R, Ranchor AV. Identification and prediction of distress trajectories in the first year after a breast cancer diagnosis. Health Psychol. 2010;29:160–8.

    Article  PubMed  Google Scholar 

  35. van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg, et al. Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer. 2013. doi:10.1007/s00520-013-2041-y.

    PubMed Central  PubMed  Google Scholar 

  36. Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt M, et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Tr. 2013;138:185–91.

    Article  CAS  Google Scholar 

  37. Kostev K, Waehlert L, Jockwig A, Jockwig B, Hadji P. Physicians’ influence on breast cancer patient compliance. GMS Ger Med Sci. 2014;12(Doc03):20140120.

    Google Scholar 

  38. Huiart L, Bouhnik A-D, Rey D, Rousseau F, Retornaz F, Meresse M, et al. Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. PLoS One. 2013;8:e81677.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric. 2013;00:1–8.

    Google Scholar 

  40. Kostev K, May U, Hog D, Eisel J, Kremmers T, Kosteic M, et al. Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany. Int J Clin Pharm Th. 2013;51:969–75.

    Article  CAS  Google Scholar 

  41. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns. 2005;59:97–102.

    Article  PubMed  Google Scholar 

  42. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care. 2007;45:431–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Alan J. Christensen’s time in preparation of this article was supported, in part, by the Behavioral Research Program in the Division of Cancer Control and Population Sciences, National Cancer Institute and the Office of Social and Behavioral Sciences Research at the National Institutes of Health.

Conflict of interest

All authors declare that they have no conflict of interest.

Informed consent/animal studies

No animal or human studies were carried out by the authors for this article.

Author information

Authors and Affiliations

  1. Department of Psychology, The University of Iowa, E11 SSH, Iowa City, IA, 52242, USA

    Julia R. Van Liew

  2. Departments of Psychology and Internal Medicine, The University of Iowa, E11 SSH, Iowa City, IA, 52242, USA

    Alan J. Christensen

  3. Health Services and Economics Branch, Division of Cancer Control and Population Sciences, National Cancer Institute/NIH, 9609 Medical Center Drive, 4E426, Bethesda, MD, 20892, USA

    Janet S. de Moor

Authors
  1. Julia R. Van Liew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan J. Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Janet S. de Moor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia R. Van Liew.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Van Liew, J.R., Christensen, A.J. & de Moor, J.S. Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv 8, 521–531 (2014). https://doi.org/10.1007/s11764-014-0374-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11764-014-0374-2

Keywords

Search

Navigation